Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 03.04.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ng the filing of the Form 25 with the SEC. Item 5.02 Departure of Directors or Certain Officers; Election of Directors |
| 03.04.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ng the filing of the Form 25 with the SEC. Item 5.02 Departure of Directors or Certain Officers; Election of Directors |
| 06.02.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ge Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Off |
| 04.02.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ge Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Off |
| 30.12.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Offi |
| 18.12.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ge Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Off |
| 13.12.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ge Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Off |
| 22.11.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | of its compliance with these requirements. Item 5.02 Departure of Directors or Certain Officers; Election of Directors |
| 20.11.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ge Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Offi |
| 09.10.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ompliance with other Nasdaq Listing Rules. Item 5.02. Departure of Directors or Certain Officers; Election of Director |
| 07.10.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ompliance with other Nasdaq Listing Rules. Item 5.02. Departure of Directors or Certain Officers; Election of Director |
| 03.10.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Act. ☐ Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal O |
| 25.09.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | lation S-K and the related instructions). Item 5.02. Departure of Directors or Certain Officers; Election of Directors |
| 17.09.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Offi |
| 30.07.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | the minimum requirement of $2,500,000. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; |
| 08.07.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ity of the Company’s Board of Directors. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; |
| 02.05.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
| 07.12.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
| 17.11.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
| 16.08.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
Stammdaten
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical nonsteroidal anti-inflammatory drug treatment for chronic osteoarthritis of the knee; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise PES200, which enables the delivery of a metabolically labile peptide drug into the brain; AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and VRP324, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.
Unternehmen & Branche
| Name | Virpax Pharmaceuticals, Inc. |
|---|---|
| Ticker | VRPX |
| CIK | 0001708331 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 13.792 USD |
| Beta | 2,44 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2024-12-31 | 10-K | -12,067,225 | -2.84 | 1,555,614 | -913,760 | |
| 2024-09-30 | 10-Q | -2,006,456 | -0.43 | 304,162 | -2,051,612 | |
| 2024-06-30 | 10-Q | -3,450,256 | -1.75 | 2,590,609 | -2,794,498 | |
| 2024-03-31 | 10-Q | -3,220,424 | -2.75 | 3,130,407 | -1,213,384 | |
| 2023-12-31 | 10-K | -15,189,508 | -12.97 | 9,628,345 | 1,934,321 | |
| 2023-09-30 | 10-Q | -5,994,498 | -5.12 | 13,038,387 | 6,505,664 | |
| 2023-06-30 | 10-Q | -3,112,767 | -2.66 | 15,951,368 | 12,304,598 | |
| 2023-03-31 | 10-Q | -1,520,534 | -1.30 | 18,493,347 | 15,199,108 | |
| 2022-12-31 | 10-K | -21,650,720 | -18.49 | 19,673,649 | 16,579,059 | |
| 2022-09-30 | 10-Q | -7,641,890 | -0.65 | 23,635,761 | 19,427,896 | |
| 2022-06-30 | 10-Q | -5,884,715 | -0.50 | 29,402,442 | 26,919,069 | |
| 2022-03-31 | 10-Q | -5,137,002 | -0.44 | 34,745,974 | 32,559,083 | |
| 2021-12-31 | 10-K | -12,056,063 | -1.81 | 39,572,436 | 37,484,745 | |
| 2021-09-30 | 10-Q | -3,215,744 | -0.53 | 43,273,033 | 41,461,224 | |
| 2021-06-30 | 10-Q | -2,343,419 | -0.47 | 11,387,696 | 7,535,730 | |
| 2021-03-31 | 10-Q | -2,379,271 | 13,219,342 | 9,557,722 | ||
| 2020-12-31 | 10-K | -4,339,653 | 465,406 | -4,216,098 | ||
| 2020-09-30 | 10-Q | -1,708,163 | -3,846,433 | |||
| 2020-06-30 | 10-Q | -1,269,784 | -2,684,067 | |||
| 2020-03-31 | 10-Q | -656,495 | -2,830,999 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.